Detalhe da pesquisa
1.
A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid Tumors.
Oncologist
; 29(1): e131-e140, 2024 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37531083
2.
A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer.
Gynecol Oncol
; 167(2): 213-225, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36192237
3.
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study.
Lancet Oncol
; 22(10): 1468-1482, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34592180
4.
Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings.
Oncologist
; 25(11): e1628-e1639, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32537847
5.
A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer.
Clin Lung Cancer
; 22(6): 531-540, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34034991
6.
Suppression of p53 and p21CIP1/WAF1 reduces arsenite-induced aneuploidy.
Chem Res Toxicol
; 23(2): 357-64, 2010 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20000476
7.
Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial.
Cancers (Basel)
; 12(10)2020 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33076423
8.
A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib.
Oncotarget
; 11(3): 216-236, 2020 Jan 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32076484
9.
Achieving Precision Death with Cell-Cycle Inhibitors that Target DNA Replication and Repair.
Clin Cancer Res
; 23(13): 3232-3240, 2017 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28331049
10.
Exit from arsenite-induced mitotic arrest is p53 dependent.
Environ Health Perspect
; 114(9): 1401-6, 2006 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-16966095
11.
LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms.
Mol Cancer Ther
; 14(9): 2004-13, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26141948
12.
The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells.
Mol Cancer Ther
; 11(8): 1781-8, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22653969
13.
Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase.
Cell Cycle
; 9(5): 995-1004, 2010 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20160494
14.
Mitotic arrest-associated apoptosis induced by sodium arsenite in A375 melanoma cells is BUBR1-dependent.
Toxicol Appl Pharmacol
; 231(1): 61-7, 2008 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18501396
15.
Arsenite-induced mitotic death involves stress response and is independent of tubulin polymerization.
Toxicol Appl Pharmacol
; 230(2): 235-46, 2008 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18485433
16.
Sensitivity to sodium arsenite in human melanoma cells depends upon susceptibility to arsenite-induced mitotic arrest.
Toxicol Appl Pharmacol
; 229(2): 252-61, 2008 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18328521
17.
p53 suppression of arsenite-induced mitotic catastrophe is mediated by p21CIP1/WAF1.
J Pharmacol Exp Ther
; 318(1): 142-51, 2006 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-16614167
18.
Arsenite disrupts mitosis and induces apoptosis in SV40-transformed human skin fibroblasts.
Toxicol Appl Pharmacol
; 180(2): 83-91, 2002 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-11969375